Boston, MA 06/10/2014 (wallstreetpr) – Rite Aid Corporation (NYSE:RAD) has evolved over the last couple of years from the brink of bankruptcy to becoming a popular success story.
The Voluminous ‘Drop’
In 2013, Rite Aid Corporation (NYSE:RAD)’s share prices escalated a whopping 155%, and the trend continued in FY 2014 as well, through thick and thin. However, the stock witnessed a slackening trade activity off late, as it provided a rather meek valued guidance for FY 2015, estimating an annual income in the range of $298 and $408 million. Eventually, this resulted in a significant drop in trade activity by 4.40% on Monday.
RAD Unveils Innovative Memory Tests
Rite Aid Corporation (NYSE:RAD) has disclosed earlier today that it shall provide customers options to avail detailed memory tests from June 2014 onward, in a bid to procure early warnings for Alzheimer’s Disease among people.
This innovative endeavor has drawn scathing comments from the fraternity of doctors, as the latter stated outright that the procedure adopted by RAD is flawed and might infuse unwarranted fear among individuals who are not suffering from this dismal disease.
The drugstore chain has corroborated that they have partnered with Alzheimer’s Foundation of America (a not-for-profit group of clinical advocates) to take five to ten minutes’ verbal and written tests to trace symptoms of Dementia and Alzheimer’s; the paper test has been dubbed as Mini-Cog.The tests would be made available across more than 4K sites in the US.
Opinions And Dissent
The Foundation’s eminent President, Carol Steinberg, commented that these tests would serve as yardsticks, spurring an examinee to visit a doctor, much early in the disease’s lifecycle. However, physicians argued that the tests are mere hogwash and is a poor scheme to churn bucks from individuals, wasting their time and inflicting them with worries of disease, which they might never suffer from!
Seconding the physicians, a Chicago-based Alzheimer’s Association also raised concerns on to the degree of veritable analysis of this ingenuous endeavor. A spokesperson for the Pennsylvania-based Rite Aid Corporation (NYSE:RAD), Ashley Flower commented that the company has instructed and taught the pharmacists on the ways to properly administer the AFA screening.
The impact of Rite Aid Corporation (NYSE:RAD)’s memory tests is the talking point as opinions of dissent are fluttering in myriad quarters, however, this endeavor has received a thumb’s-up from various fraternities. In the investors’ perspective, the company will notch up significant revenues in the upcoming months, from these memory tests; hence, RAD shares may evolve as a prospective, yet risky buy!